Navigation Links
Mylan Launches First Generic Version of Entocort EC® Capsules
Date:6/23/2011

PITTSBURGH, June 23, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of Delaware has found after trial that Mylan subsidiary Mylan Pharmaceuticals Inc. does not infringe the asserted claims of U.S. Patent No. 5,643,602 with its Abbreviated New Drug Application (ANDA) for Budesonide Capsules, 3 mg (Enteric Coated), the generic version of AstraZeneca's Entocort EC® capsules, a treatment for Crohn's disease.  

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Budesonide Capsules, 3 mg, ANDA on May 16. This is the first generic version of this product to be introduced to the U.S. market, and Mylan Pharmaceuticals will be shipping this product immediately.

Budesonide Capsules, 3 mg, had U.S. sales of approximately $350 million for the 12 months ending March 31, 2011, according to IMS Health.

Currently, Mylan has 164 ANDAs pending FDA approval representing $94.2 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $25.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Receives Approval for Generic Version of Aricept® Tablets
2. Mylan Receives Approval for Generic Version of Effexor XR® Capsules
3. Mylan Launches Generic Version of Roxicodone® Tablets
4. Mylan Launches Generic Version of Depakote® Sprinkle Capsules
5. Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
6. Mylan Launches First Generic Version of Amrix® Capsules
7. Mylan Launches Generic Version of Risperdal® M-Tab®
8. Mylan Launches First Generic Version of Femara® Tablets
9. Mylan Launches Generic Version of Famvir® Tablets
10. Mylan Receives Approval for Generic Version of Xalatan® Ophthalmic Solution
11. Mylan Announces Exclusive Distribution Partnership with Humeca to Expand Burn and Wound Care Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... 2, 2016 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... , , ... in 2015, and it is expected to grow at a CAGR of ... to witness faster growth during the forecast period, a CAGR of 8.8% ...
(Date:12/2/2016)... Dec. 2, 2016 In the first ever ... from those derived from C. sativa, the Hebrew University ... di Napoli Federico II , the Universita` del Piemonte ... comprehensive, critical, integrated and unified inventory of phytocannabinoids of ... focuses on the remarkable chemical and structural diversity of ...
(Date:12/2/2016)... , Dec. 2, 2016  Maxor National Pharmacy Services, ... of Pharmaceutical Specialties, Inc. ("PSI").  The combination of ... Georgia -based PSI bring together both company,s clinical ... manufacturers, and payers an industry-leading specialty pharmacy. About ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... today that they have teamed up with The American College of Surgeons (ACS) ... ACS’s Committee on Trauma, the “Bleeding Control Basic” course is a pilot program ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Tasting Event in New York City, with long-time partners The Paul Foundation, on ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... ... December 04, 2016 , ... ... cosmetic surgery can now take advantage of a cosmetic procedure known as ... treatment that reduces the appearance of age spots, fine lines, uneven coloration, ...
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with First 5 ... services to more than 15,900 children 5 years old and younger and treatment services ... over a span of five years to Western University of Health Sciences, UCLA and ...
Breaking Medicine News(10 mins):